Calfactant for Direct Acute Respiratory Distress Syndrome - Full Text View

Sponsored by:	Pneuma Pharmaceuticals Incorporated
Information provided by:	Pneuma Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier:	NCT00682500

Purpose

This study will determine if administration of an suspension of calfactant, a lung surfactant, intratracheally in patients with Direct Acute Respiratory Distress Syndrome within 48 hours of requiring mechanical ventilation can decrease the mortality in patients with lethal disease and shorten the course of respiratory failure in patients with sub-lethal disease.

Condition	Intervention	Phase
Respiratory Distress Syndrome, Adult	Drug: Calfactant Drug: Room Air (placebo)	Phase III

Drug Information available for: Calfactant

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study
Official Title:	Calfactant Therapy for Direct Acute Respiratory Distress Syndrome & Direct Acute Lung Injury in Adults and Children

Further study details as provided by Pneuma Pharmaceuticals Incorporated:

Primary Outcome Measures:

Mortality Rate [ Time Frame: 90 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Duration of mechanical ventilation [ Time Frame: 90 days ] [ Designated as safety issue: No ]

Estimated Enrollment:	480
Study Start Date:	May 2008
Estimated Study Completion Date:	September 2010
Estimated Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Calfactant treatment	Drug: Calfactant Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
2: Placebo Comparator	Drug: Room Air (placebo) Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met

Detailed Description:

Recruitment limited to direct adult respiratory distress syndrome patients who have been intubated <48 hours. Origin of ARDS must be infectious pneumonia, aspiration of stomach contents, near drowning, smoke inhalation without pulmonary burn, inhaled industrial gas.

Eligibility

Ages Eligible for Study:	1 Month to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Respiratory failure due to diffuse infectious pneumonia, aspiration, near drowning, smoke inhalation or industrial gas
Less than 48 hours of mechanical ventilation
Informed consent

Exclusion Criteria:

Pre-existing lung disease
coma
limited therapeutic goals (do not resuscitate, etc.)
failure of another vital organ

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00682500

Contacts

Contact: Christine Traul, MD	434-982-3973	CT6Q@hscmail.mcc.virginia.edu
Contact: Douglas Willson, MD	434-982-1707	dfw4m@virginia.edu

Show 34 Study Locations

Sponsors and Collaborators

Pneuma Pharmaceuticals Incorporated

Investigators

Study Chair:	Douglas Willson, MD	Univeristy of Virginia Health Sciences Center
Study Chair:	Jonathon Truwit, MD	University of Virginia Health Sciences Center

More Information

No publications provided

Responsible Party:	University of Virginia Health Science Center ( Douglas Willson, MD )
Study ID Numbers:	Pneuma AR-06
Study First Received:	May 20, 2008
Last Updated:	February 5, 2009
ClinicalTrials.gov Identifier:	NCT00682500 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pneuma Pharmaceuticals Incorporated:

Pneumonia
Aspiration
Drowning
inhalation

Study placed in the following topic categories:

Respiratory Tract Diseases
Drowning
Lung Diseases
Respiration Disorders
Respiratory Distress Syndrome, Adult

Acute Respiratory Distress Syndrome
Calfactant
Pneumonia
Pulmonary Surfactants

Additional relevant MeSH terms:

Respiratory System Agents
Pathologic Processes
Disease
Respiratory Tract Diseases
Therapeutic Uses
Lung Diseases

Syndrome
Respiration Disorders
Respiratory Distress Syndrome, Adult
Calfactant
Pharmacologic Actions
Pulmonary Surfactants

ClinicalTrials.gov processed this record on May 07, 2009